Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized, double-blinded, placebo-controlled phase 3 trials (ADvocate1 and ADvocate2)

被引：0

作者：

Blauvelt, Andrew ^{[1
]}

Thyssen, Jacob P. ^{[2
]}

Guttman-Yassky, Emma ^{[3
]}

Bieber, Thomas ^{[4
]}

Carrascosa, Jose Manuel ^{[5
]}

Simpson, Eric ^{[6
]}

Rosmarin, David ^{[7
]}

Elmaraghy, Hany ^{[8
]}

Meskimen, Eric ^{[8
]}

Natalie, Chitra R. ^{[8
]}

Liu, Zhuqing ^{[8
]}

Xu, Chenjia ^{[8
]}

Pierce, Evangeline ^{[8
]}

Morgan-Cox, MaryAnn ^{[8
]}

Silverberg, Jonathan, I ^{[9
]}

机构：

[1] Oregon Med Res Ctr, Portland, OR 97223 USA

[2] Univ Copenhagen, Bispebjerg Hosp, Copenhagen, Denmark

[3] Icahn Sch Med Mt Sinai, New York, NY USA

[4] Univ Hosp Bonn, Bonn, Germany

[5] UAB, Germans Trias i Pujol Univ Hosp, IGTP, Barcelona, Spain

[6] Oregon Hlth & Sci Univ, Portland, OR USA

[7] Tufts Univ, Sch Med, Boston, MA USA

[8] Eli Lilly & Co, Indianapolis, IN USA

[9] George Washington Univ, Sch Med & Hlth Sci, Washington, DC USA

来源：

BRITISH JOURNAL OF DERMATOLOGY | 2023年 / 188卷

关键词：

monotherapy; atopic dermatitis; moderate-to-severe; lebrikizumab; interleukin (IL)-13;

D O I：

10.1093/bjd/ljac140.018

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

322

引用

页数：2

共 50 条

[21] Lebrikizumab is associated with improvements in patient-reported symptoms and quality-of-life measures across Eczema Area and Severity Index response categories: pooled results from phase-3 randomized ADvocate1 and ADvocate2 studies in patients with moderate-to-severe atopic dermatitis
Blauvelt, Andrew
Kircik, Leon
Schlesinger, Todd
Pierce, Evangeline
Burge, Russel
Behling, Michael
Atwater, Amber Reck
Elmaraghy, Hany
Armstrong, April
JOURNAL OF DERMATOLOGICAL TREATMENT, 2025, 36 (01)
[22] Efficacy and safety of lebrikizumab in combination with topical corticosteroids in patients with moderate-to-severe atopic dermatitis: a phase III randomized, placebo-controlled trial (ADhere)
Simpson, Eric L.
Gooderham, Melinda
Wollenberg, Andreas
Weidinger, Stephan
Armstrong, April
Soung, Jennifer
Ferrucci, Silvia
Lima, Renata Gontijo
Xu, Wen
Witte, Michael M.
Blauvelt, Andrew
BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 (03) : E108 - E108
[23] Long-term efficacy and safety of stapokibart for moderate-to-severe atopic dermatitis: 52-week results from a phase 3 trial
Zhao, Yan
Zhang, Litao
Wu, Liming
Yang, Bin
Wang, Jinyan
Li, Yumei
Li, Jingyi
Diao, Qingchun
Sun, Qing
Zhu, Xiaohong
Man, Xiaoyong
Wang, Lihua
Li, Linfeng
Feng, Yanyan
Zeng, Huiming
Cai, Tao
Ren, Hong
Lu, Jianyun
Lu, Qianjin
Tao, Xiaohua
Xiao, Rong
Ji, Chao
Li, Fuqiu
Zhang, Jianzhong
ALLERGY, 2024,
[24] Dupilumab prevents flares in adults with moderate-to-severe atopic dermatitis in a 52-week, randomized, controlled, phase 3 trial
Merola, J. F.
Sidbury, R.
Wollenberg, A.
Chen, Z.
Zhang, A.
Shumel, B.
Rossi, A. B.
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2020, 140 (07) : S53 - S53
[25] Dupilumab for Adolescents With Moderate-to-Severe Atopic Dermatitis: Results From a Phase 3, Randomized, Double-Blinded Trial
Paller, A.
Blauvelt, A.
Pariser, D.
Soong, W.
Hong, H. C-H
Zhang, R.
Eckert, L.
Gadkari, A.
Hultsch, T.
Bansal, A.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2019, 17 : 116 - 116
[26] Dupilumab for adolescents with moderate-to-severe atopic dermatitis: Results from a phase 3, randomized, double-blinded trial
Paller, A.
Blauvelt, A.
Pariser, D.
Worrell, R.
Soong, W.
Hong, C.
Zhang, R.
Eckert, L.
Gadkari, A.
Hultsch, T.
Bansal, A.
AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2019, 60 : 69 - 69
[27] Dupilumab for adolescents with moderate-to-severe atopic dermatitis: Results from a phase 3, randomized, double-blinded trial
Paller, Amy S.
Blauvelt, Andrew
Pariser, David M.
Soong, Wiley
Hong, H. Chih-ho
Zhang, Rick
Eckert, Laurent
Gadkari, Abhijit
Hultsch, Thomas
Bansal, Ashish
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB195 - AB195
[28] Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis
Ryan, C.
Menter, A.
Guenther, L.
Blauvelt, A.
Bissonnette, R.
Meeuwis, K.
Sullivan, J.
Cather, J. C.
Yosipovitch, G.
Gottlieb, A. B.
Merola, J. F.
Duffin, K. Callis
Fretzin, S.
Osuntokun, O. O.
Burge, R.
Naegeli, A. N.
Yang, F. E.
Lin, C. -Y.
Todd, K.
Bleakman, A. Potts
BRITISH JOURNAL OF DERMATOLOGY, 2018, 179 (04) : 844 - 852
[29] Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study
Guttman-Yassky, Emma
Silverberg, Jonathan I.
Nemoto, Osamu
Forman, Seth B.
Wilke, August
Prescilla, Randy
de la Pena, Amparo
Nunes, Fabio P.
Janes, Jonathan
Gamalo, Margaret
Donley, David
Paik, Jim
DeLozier, Amy M.
Nickoloff, Brian J.
Simpson, Eric L.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 80 (04) : 913 - +
[30] The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE)
Reich, K.
Gooderham, M.
Green, L.
Bewley, A.
Zhang, Z.
Khanskaya, I.
Day, R. M.
Goncalves, J.
Shah, K.
Piguet, V.
Soung, J.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 (03) : 507 - 517

← 1 2 3 4 5 →